Compare RPID & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPID | ELUT |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.7M | 35.6M |
| IPO Year | 2021 | 2020 |
| Metric | RPID | ELUT |
|---|---|---|
| Price | $0.74 | $0.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 151.4K | 70.2K |
| Earning Date | 11-27-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.78 | ★ 146.77 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,587,000.00 | $12,293,000.00 |
| Revenue This Year | $16.95 | N/A |
| Revenue Next Year | $17.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.74 | N/A |
| 52 Week Low | $0.58 | $0.50 |
| 52 Week High | $4.94 | $1.39 |
| Indicator | RPID | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 47.95 |
| Support Level | $0.58 | $0.73 |
| Resistance Level | $2.18 | $0.87 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 66.24 | 43.48 |
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.